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Introduction
Estrogen is an important female hormone. It has several
roles in gynecology and obstetrics. Estrogen receptors
(ERs), both α and β types, are members of the steroid/
thyroid nuclear receptor superfamily of ligand-dependent
transcription factors [1]. The impact of ER-α on breast
cancer pathophysiology and disease progression is now
well established [1,2], and the ER gene has been stud-
ied in many clinical conditions. Pathologic aberrations
of ER structure and function are a major cause of estro-
gen insensitivity in affected females and a possible un-
derlying cause of breast cancer. Indeed, estrogen plays
important roles in the pathologic proliferation of can-
cer cells in reproductive organs, especially those pro-
cesses in the pathologies of the breast and uterus [3].
Based on the observation of bilateral risks and fre-
quent multifocality with atypical ductal hyperplasia,
atypical lobular hyperplasia and lobular breast carci-
noma in situ, it is concluded that estrogen may represent
both risk factors and precursors [4]. ER-β-positivity and
ER-α-negativity can characterize the highest levels of
proliferative breast cancer cell activity [4].
Many naturally occurring splice variants of both ER
isoforms have been detected in normal epithelium and
in diseased or cancerous tissues [5]. In contrast, only a
few ER point mutations have been confirmed in human
patient samples from a variety of disease states, includ-
ing breast cancer, endometrial cancer and some spe-
cific psychiatric diseases [5]. Depth analysis of the ER
can improve our understanding of the pathogenesis of
ER-related disorders. The prevalence of mutations in
the ER receptor gene is unknown. Analysis of mutation-
susceptible positions in the ER is the first step in fur-
thering research into ER mutations, followed by the
functional characterization of these mutations.
The prediction of protein nanostructure and function
is a major focus of proteomic and genomic research.
Identification of points vulnerable to mutation is a new
approach that could extend our understanding of many
diseases at the genomic and proteomic level [6,7].
Mutated regions in proteins usually contain specific,
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Mutations Within ER
short linear peptide motifs that are crucial for protein
function. Identification of these peptide motifs in the
amino acid sequence can help to predict the weak 
linkages in a protein [6,7]. In this study, the author
performed bioinformatics analysis to determine the
vulnerable positions characterized by those specific
peptide motifs in the amino acid sequence of the ER.
Materials and Methods
Determination of the ER sequence
The Expert Protein Analysis System (ExPASy) [8] was
used to determine the amino acid sequence of the ER.
ExPASy is a proteomics server copyrighted to the Swiss
Institute of Bioinformatics [8]. ExPASy is designed for the
analysis of protein sequences and structures, as well as
for two-dimensional polyacrylamide gel electrophoresis
[8]. The derived ER sequence was used as a template
sequence for identifying weak linkages within the ER.
Identification of weak linkages within the ER
A computational tool called GlobPlot [9] was used 
to identify weak linkages in the ER using bioinformat-
ics techniques. GlobPlot is a web-based service aimed
at helping researchers to plot tendencies for order/
globularity and disorder in target proteins [9]. The spe-
cific interface is simple to use; pasting a sequence or
entering the SWISS-PROT/SWALL accession or entry
code allows further bioinformatics analysis to be per-
formed [9]. Functionally, the GlobPlot server retrieves
the entered sequence and a description of the poly-
peptide from an ExPASy server using Biopython.org
software. Putative globular and disorder segments are
further selected using a simple peak finder algorithm
known as PeakFinder [9]. Specific identified peaks are
selected when the first derivative shows positive values
over a continuous stretch of a minimum length [9].
Using this bioinformatics process, GlobPlot can iden-
tify inter-domain segments containing linear motifs
and ordered regions with no recognized domains [9].
Theoretically, the resulting determined motifs are the
weak linkages in a protein that are prone to point
mutations [6,7].
Results
The ER sequence (P81559) was derived by ExPASy
searching and was then used for further study. Several
motifs were identified (as shown in the Figure). Positions
1–10, 51–55, 84–101, 144–173, 212–219, 548–571 and
580–584 were identified as resistant positions.
Discussion
The temporal and tissue-specific actions of estrogen
are physiologically mediated by ERs α and β [10]. ERs
are steroid hormone receptors that modulate the tran-
scription of target genes when specifically bound to
their ligand [10]. There is a large and increasing body
of experimental and clinical data supporting the exis-
tence of variant forms of ER proteins in both normal
and neoplastic estrogen target tissues, including human
breast tissue [11]. The physiologic and pathologic func-
tions of variant ER proteins remain unclear, though a
role for some ER variants in breast tumorigenesis and
breast cancer progression would be consistent with
the accumulated published data [11].
ER mutations are involved in some rare syndromes
characterized by estrogen disorders, while the molecu-
lar pathophysiology of other ER disorders, including
breast cancer, are associated with post-receptor modi-
fications. Identification of the mutation points within
the ER can be useful for furthering research into the
pathogenesis of these estrogen disorders. However, iden-
tification of ER mutation points using classical in vitro
experiments is time consuming and has a low probabil-
ity of identifying positive cases. Developments in bio-
informatics, however, can help to solve this problem
[12]. In this study, the author used a computational
bioinformatics algorithm to identify the positions in
the ER amino acid sequence that were susceptible to
MTMPLPNKTT gvtflhqiqs seletltrpp lkislerplg emyvennrtg IFNYPegtty dfaaaaapvy ssaslsyaas setFGSSSLT
GLHTLNNVPP Spvvflaklp qlspfihhhg qqvpyylese qgtfavreaa pptFYRSSSD NRRQSGRERM SSANDKGPPS MEStketryc
avcsdyasgy hygvwscegc kaffkrsiqg hNDYMCPATn qctidknrrk scqacrlrkc yevgmmkggi rkdrrggrll khkrqkeeqe
qkndvdpsei rtasiwvnps vksmklspvl sltaeqlisa lmeaeapivy sehdstkpls easmmtlltn ladrelvhmi nwakrvpgfv
dltlhdqvhl lecawleilm vgliwrsveh pgklsfapnl lldrnqgrcv eglveifdml vttatrfrmm rlrgeeficl ksiillnsgv
ytflsstles ledtdlihii ldkiidtlvh fmaksglslq qqqrrlaqll lilshirhms nkgmehlysm kcknvvplyd lllemldahr
ihtpkdkTTT QEEDSRSPPT TTVNGASPCL QpyytnteeV SLQStv
Lower case letters represent amino acids and upper case letters represent resistant positions.
Figure. Mutation-resistant and mutation-prone positions within the estrogen receptor amino acid sequence.
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mutation. The standard protein database tool ExPASy
was used for the initial data-searching step. This com-
putational database tool has been widely used and can
produce highly reliable results [13]. GlobPlot was used
for further identification of mutation-prone sites within
the ER. This new technique has been used to identify
mutations in many previously published studies [14–18].
In the current study, the tool successfully identified
several positions. Some of these positions were previ-
ously-documented mutation points, whereas others
were identified for the first time in this study. Based on
these data, the weak linkages in the ER can be success-
fully identified and can provide useful data for further
studies aimed at predicting possible new ER mutations
associated with overt ER abnormalities. Further trans-
lational research is needed to relate phenotypic expres-
sion to the mutation-prone positions in the ER. These
results will also be useful for further functional character-
ization predictions, which can be performed using new
gene ontology technology techniques [19,20]. The func-
tional significance of the identified mutation-resistant
locations within the ER should also be further assessed
and functionally characterized in future studies.
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